← Back to Search

Other

Ringer's lactate for Diabetic Ketoacidosis (BRISK-ED Trial)

N/A
Waitlist Available
Led By Justin W Yan, MD, MSc
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

Summary

This study is evaluating whether a surgery which reduces blood flow in a stomach artery leads to significant weightloss.

Eligible Conditions
  • Diabetic Ketoacidosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patient recruitment rate (feasibility outcome)
Time to DKA resolution (efficacy outcome)
Secondary outcome measures
Hospital length of stay
Hyper- or hypo-kalemia post-emergency department
In-hospital acute kidney injury (Stage 2 or greater) post-emergency department
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ringer's lactateExperimental Treatment1 Intervention
The intervention is administration of IV Ringer's lactate. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
Group II: Normal salineActive Control1 Intervention
The comparator is administration of IV normal saline. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
666 Previous Clinical Trials
414,214 Total Patients Enrolled
Justin W Yan, MD, MScPrincipal InvestigatorLawson Health Research Institute/Western University
~14 spots leftby Jul 2025